2007
DOI: 10.1159/000108387
|View full text |Cite
|
Sign up to set email alerts
|

Long-Term Safety and Efficacy of Ivabradine in Patients with Chronic Stable Angina

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

0
69
0
1

Year Published

2008
2008
2023
2023

Publication Types

Select...
3
3
1

Relationship

0
7

Authors

Journals

citations
Cited by 63 publications
(70 citation statements)
references
References 27 publications
0
69
0
1
Order By: Relevance
“…40 Heart rate was slowed in both treatment groups, with excessive sinus bradycardia and heart rate less than 40 bpm reportedly occurring in 2 patients in the 7.5 mg twice-daily group. 40 There was a mean increase in QT interval, but when corrected with the Bazett formula, the QTc interval numerically decreased. 40 In a pooled analysis of the BEAUTIFUL and SHIFT trials, adverse reactions occurring more commonly than with placebo included symptomatic and asymptomatic bradycardia (4% each), atrial fibrillation (8%), phosphenes (3%), and blurred vision (0.8%).…”
Section: Adverse Reactionsmentioning
confidence: 90%
See 3 more Smart Citations
“…40 Heart rate was slowed in both treatment groups, with excessive sinus bradycardia and heart rate less than 40 bpm reportedly occurring in 2 patients in the 7.5 mg twice-daily group. 40 There was a mean increase in QT interval, but when corrected with the Bazett formula, the QTc interval numerically decreased. 40 In a pooled analysis of the BEAUTIFUL and SHIFT trials, adverse reactions occurring more commonly than with placebo included symptomatic and asymptomatic bradycardia (4% each), atrial fibrillation (8%), phosphenes (3%), and blurred vision (0.8%).…”
Section: Adverse Reactionsmentioning
confidence: 90%
“…40 There was a mean increase in QT interval, but when corrected with the Bazett formula, the QTc interval numerically decreased. 40 In a pooled analysis of the BEAUTIFUL and SHIFT trials, adverse reactions occurring more commonly than with placebo included symptomatic and asymptomatic bradycardia (4% each), atrial fibrillation (8%), phosphenes (3%), and blurred vision (0.8%). 32 These adverse events were similar to those reported in the largest randomized controlled trial.…”
Section: Adverse Reactionsmentioning
confidence: 96%
See 2 more Smart Citations
“…Ivabradine substantially reduced the frequency of angina attacks and the consumption of short-acting nitrates compared with placebo, 6 standard antinational therapies such as beta-blocker or calcium channel blocker 7,8 in the shortterm (2 to 3 months) and maintained antianginal efficacy in long-term (1 year) therapy without development of pharmacological tolerance. 9 Ivabradine also showed significant anti-ischaemic efficacy and improvement of exercise capacity, which are important clinically for angina. Ivabradine demonstrated improvements in time to 1-mm ST-segment depression, to angina onset, and to limiting angina in monotherapy 6,7 or in patients receiving betablocker therapy.…”
Section: Symptomatic Treatment In Patients With Stable Angina Pectorismentioning
confidence: 97%